DougGuitarPlayer :
My wife was treated with Tarceva since being diagnosed with Stage IV NSCLC on March 29th, 2013. As of today, the tumors are again growing and therefore becoming resistant to the Tarceva. Her doctor at Dana Farber recommends getting into the trial for AZD 9291, however, we were told that the trial at Dana Farber is currently closed, and may reopen in January 2014. It is not clear whether you will need to demonstrate a T790M mutation to be accepted into the trial. By the way, the recommended plan C was chemo and continue Tarceva for a period.
There was also some discussion whether getting into a Clovis trial would be a better option, but that is not offered at Dana Farber.
Given that we have few options we are hoping to hear some positive stories from the trials of AZD 9291.
===================================================================
Diceros :
We live in the UK where AZD9291 is on clinical trial. My wife has been taking it for about six months. It has reduced her tumour by about two-thirds so far. The side effects have been minimal. The hope of course is that this drug will not only shrink the tumour but stop it regrowing and spreading.
DougGuitarPlayer :
我的妻子于2013年4月29日诊断出是4期NSCLC,同时开始服用特罗凯。到今天,肿瘤又开始生长了,显示已经对特罗凯耐药了。她在丹娜法伯癌症研究院的医生建议她入组9291的临床。但是我们被告知,丹娜法伯的临床已经关闭了,要到2014年1月才可能重开。不清楚是否需要检测出有T790M的表达才能入组。顺便说一下,医生给的第三种建议是化疗之后继续服用特罗凯一段时间。
有一些讨论说可能CLVS的1686是个更好的选择,但丹娜法伯没有临床。
我们只有这些选择了,所以很希望能够听到来自9291临床的正面消息。
Diceros :
我们来自英国,英国的9291已经开始临床了。我妻子已经服用了近6个月了。她体内的肿瘤缩小了三分之二,副作用几乎没有。希望这个药不仅仅能够缩小肿瘤,还能够阻止它再次生长和扩散。 |